Off-label drug use among hospitalised children: identifying areas with the highest need for research
- 375 Downloads
Objective of the study To analyse the off-label use of drugs on a paediatric ward in Germany, and to identify domains of pharmacotherapy with the highest need for research concerning off-label use in children. Setting A prospective observational study was conducted on a paediatric ward in Duesseldorf in Germany between January and June 2006. Method Data about patients, diagnoses and prescribed drugs were collected from the prescription records and the discharge letters. Diagnoses were classified in groups by means of the International Classification of Diseases. Drugs were grouped according to the Anatomical Therapeutic Chemical Classification system. We compared the off-label prescriptions with those on the list of paediatric needs and priority list established by the European Medicines Agency (EMEA). Main outcome measure Off-label use was defined due to age, indication, route of application and dose. Results The study included 417 patients. We analysed 1,812 prescriptions representing 211 different drugs. In total, 253 patients (61%) received at least one off-label prescription. Of all analysed prescriptions, 553 (31%) were off-label. The percentage of off-label prescriptions among the five most frequently prescribed drug groups were as follows: 60% cardiovascular drugs (CV: 129/216), 42% anti-infectives (AI: 190/449), 30% drugs for respiratory system (RS: 100/335), 25% drugs for alimentary tract and metabolism (AM: 67/269) and 3% analgesics and antipyretics (AA: 8/264); with 17 drugs, the cardiovascular drugs also showed the highest number of different off-label prescribed drugs due to age: AI: 14; AM: 11; RS: 5; AA: 1. In addition, there was a nearly complete overlap between the identified off-label prescriptions in cardiovascular drugs and those listed by the EMEA to be prioritized for urgent research in Europe. Conclusion Cardiovascular drugs are a domain of pharmacotherapy, with a large need for research in paediatrics. The results of our study can guide the researcher to future trials on off-label prescriptions such as cardiovascular drugs, especially due to the fact that the identified off-label prescribed drugs in this group are also mentioned by the EMEA to be prioritized for paediatric research.
KeywordsOff-label use Cardiovascular drugs Clinical studies Children EMEA Germany
Financial support for L. H. is provided by the Syrian Ministry of Higher Education.
Possible conflicts of interests
- 13.Common Position (EC) No 7/2006 of 10 March 2006 adopted by the Council, acting in accordance with the procedure referred to in Article 251 of the Treaty establishing the European Community, with a view to adopting a Regulation of the European Parliament and of the Council on medical products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004. (2006) Official Journal of the European Union.Google Scholar
- 14.European Medicines Agency (London 2007) Updated priority list for studies into off-patent paediatric medicinal products. Doc. Ref.: EMEA/197972/2007. http://www.emea.europa.eu/pdfs/human/peg/19797207en.pdf (31 October, 2007).
- 16.Internationale Statistische Klassifikation der Krankheiten und verwandter Gesundheitsprobleme. 10. Revision. Version 2006. [International statistical classification of the diseases and related health problems. 10. Revision. Version 2006]. Deutsches Institut für Medizinische Dokumentation und Information. http://www.dimdi.de/static/de/klassi/diagnosen/icd10/htmlgm2006/fr-icd.htm (31 October, 2007).
- 17.Anatomisch-therapeutisch-chemische Klassifikation mit Tagesdosen. Amtliche Fassung des ATC-Index mit DDD-Angaben für Deutschland im Jahre 2006. [Anatomical Therapeutic Chemical Classification with daily doses. Official German ATC-classification 2006 with DDD]. Deutschen Institut für Medizinische Dokumentation und Information (DIMDI) 2006. http://wido.de/fileadmin/wido/downloads/pdf_arzneimittel/wido_arz_amtl_atc-index_0106.pdf. (31 October, 2007).
- 18.European Medicines Agency (London 2006) Assessment of the paediatric needs cardiovascular products. Doc. Ref.: EMEA/439649/2006. http://www.emea.europa.eu/pdfs/human/peg/43964906en.pdf (02 November, 2007).
- 19.Bucheler R, Meisner C, Kalchthaler B, Mohr H, Schroder H, Morike K, et al. „Off-label” Verschreibung von Arzneimitteln in der ambulanten Versorgung von Kindern und Jugendlichen. [Off-label prescribing of drugs in the ambulatory care of children and adolescents]. Dtsch Med Wochenschr 2002;127(48):2551–7.PubMedCrossRefGoogle Scholar
- 21.Laer S, Elshoff JP, Meibohm B, Weil J, Mir TS, Zhang W, et al. Development of a safe and effective pediatric dosing regimen for sotalol based on population pharmacokinetics and pharmacodynamics in children with supraventricular tachycardia. J Am Coll Cardiol 2005;46(7):1322–30.PubMedCrossRefGoogle Scholar